BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

550 related articles for article (PubMed ID: 30123970)

  • 1. Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer.
    Fogelman D; Cubillo A; García-Alfonso P; Mirón MLL; Nemunaitis J; Flora D; Borg C; Mineur L; Vieitez JM; Cohn A; Saylors G; Assad A; Switzky J; Zhou L; Bendell J
    Cancer Med; 2018 Nov; 7(11):5382-5393. PubMed ID: 30123970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies.
    Hurwitz H; Van Cutsem E; Bendell J; Hidalgo M; Li CP; Salvo MG; Macarulla T; Sahai V; Sama A; Greeno E; Yu KH; Verslype C; Dawkins F; Walker C; Clark J; O'Reilly EM
    Invest New Drugs; 2018 Aug; 36(4):683-695. PubMed ID: 29508247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer.
    Sanoff HK; Goldberg RM; Ivanova A; O'Reilly S; Kasbari SS; Kim RD; McDermott R; Moore DT; Zamboni W; Grogan W; Cohn AL; Bekaii-Saab TS; Leonard G; Ryan T; Olowokure OO; Fernando NH; McCaffrey J; El-Rayes BF; Horgan AM; Sherrill GB; Yacoub GH; O'Neil BH
    Cancer; 2018 Aug; 124(15):3118-3126. PubMed ID: 29905927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
    Grothey A; Van Cutsem E; Sobrero A; Siena S; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Tabernero J; Yoshino T; Lenz HJ; Goldberg RM; Sargent DJ; Cihon F; Cupit L; Wagner A; Laurent D;
    Lancet; 2013 Jan; 381(9863):303-12. PubMed ID: 23177514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Li J; Qin S; Xu R; Yau TC; Ma B; Pan H; Xu J; Bai Y; Chi Y; Wang L; Yeh KH; Bi F; Cheng Y; Le AT; Lin JK; Liu T; Ma D; Kappeler C; Kalmus J; Kim TW;
    Lancet Oncol; 2015 Jun; 16(6):619-29. PubMed ID: 25981818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients.
    Shitara K; Yamanaka T; Denda T; Tsuji Y; Shinozaki K; Komatsu Y; Kobayashi Y; Furuse J; Okuda H; Asayama M; Akiyoshi K; Kagawa Y; Kato T; Oki E; Ando T; Hagiwara Y; Ohashi Y; Yoshino T
    Ann Oncol; 2019 Feb; 30(2):259-265. PubMed ID: 30508156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study.
    Duffaud F; Mir O; Boudou-Rouquette P; Piperno-Neumann S; Penel N; Bompas E; Delcambre C; Kalbacher E; Italiano A; Collard O; Chevreau C; Saada E; Isambert N; Delaye J; Schiffler C; Bouvier C; Vidal V; Chabaud S; Blay JY;
    Lancet Oncol; 2019 Jan; 20(1):120-133. PubMed ID: 30477937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study.
    Van Cutsem E; Martinelli E; Cascinu S; Sobrero A; Banzi M; Seitz JF; Barone C; Ychou M; Peeters M; Brenner B; Hofheinz RD; Maiello E; André T; Spallanzani A; Garcia-Carbonero R; Arriaga YE; Verma U; Grothey A; Kappeler C; Miriyala A; Kalmus J; Falcone A; Zaniboni A
    Oncologist; 2019 Feb; 24(2):185-192. PubMed ID: 30190299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation.
    O'Shaughnessy J; DeMichele A; Ma CX; Richards P; Yardley DA; Wright GS; Kalinsky K; Steis R; Diab S; Kennealey G; Geschwindt R; Jiang W; Rugo HS
    Breast Cancer Res Treat; 2018 Aug; 170(3):547-557. PubMed ID: 29675680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed.
    Hurwitz HI; Uppal N; Wagner SA; Bendell JC; Beck JT; Wade SM; Nemunaitis JJ; Stella PJ; Pipas JM; Wainberg ZA; Manges R; Garrett WM; Hunter DS; Clark J; Leopold L; Sandor V; Levy RS
    J Clin Oncol; 2015 Dec; 33(34):4039-47. PubMed ID: 26351344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regorafenib in Patients with Antiangiogenic-Naïve and Chemotherapy-Refractory Advanced Colorectal Cancer: Results from a Phase IIb Trial.
    Riechelmann RP; Leite LS; Bariani GM; Glasberg J; Rivelli TG; da Fonseca LG; Nebuloni DR; Braghiroli MI; Queiroz MA; Isejima AM; Kappeler C; Kikuchi L; Hoff PM
    Oncologist; 2019 Sep; 24(9):1180-1187. PubMed ID: 31175167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
    Demetri GD; Reichardt P; Kang YK; Blay JY; Rutkowski P; Gelderblom H; Hohenberger P; Leahy M; von Mehren M; Joensuu H; Badalamenti G; Blackstein M; Le Cesne A; Schöffski P; Maki RG; Bauer S; Nguyen BB; Xu J; Nishida T; Chung J; Kappeler C; Kuss I; Laurent D; Casali PG;
    Lancet; 2013 Jan; 381(9863):295-302. PubMed ID: 23177515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma.
    Van Den Neste E; André M; Gastinne T; Stamatoullas A; Haioun C; Belhabri A; Reman O; Casasnovas O; Ghesquieres H; Verhoef G; Claessen MJ; Poirel HA; Copin MC; Dubois R; Vandenberghe P; Stoian IA; Cottereau AS; Bailly S; Knoops L; Morschhauser F
    Haematologica; 2018 May; 103(5):840-848. PubMed ID: 29351986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study.
    Dane F; Ozgurdal K; Yalçın Ş; Benekli M; Aykan NF; Yücel İ; Özkan M; Evrensel T; Sevinç A; Coskun HŞ; Sanli UA; Kara IO; Yumuk PF
    BMJ Open; 2020 Mar; 10(3):e027665. PubMed ID: 32220908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Mir O; Brodowicz T; Italiano A; Wallet J; Blay JY; Bertucci F; Chevreau C; Piperno-Neumann S; Bompas E; Salas S; Perrin C; Delcambre C; Liegl-Atzwanger B; Toulmonde M; Dumont S; Ray-Coquard I; Clisant S; Taieb S; Guillemet C; Rios M; Collard O; Bozec L; Cupissol D; Saada-Bouzid E; Lemaignan C; Eisterer W; Isambert N; Chaigneau L; Cesne AL; Penel N
    Lancet Oncol; 2016 Dec; 17(12):1732-1742. PubMed ID: 27751846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study.
    Van Cutsem E; Yoshino T; Lenz HJ; Lonardi S; Falcone A; Limón ML; Saunders M; Sobrero A; Park YS; Ferreiro R; Hong YS; Tomasek J; Taniguchi H; Ciardiello F; Stoehr J; Oum'Hamed Z; Vlassak S; Studeny M; Argiles G
    Ann Oncol; 2018 Sep; 29(9):1955-1963. PubMed ID: 30010751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study.
    Moriwaki T; Fukuoka S; Taniguchi H; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama C; Denda T; Satake H; Suto T; Sugimoto N; Enomoto M; Ishikawa T; Kashiwada T; Sugiyama M; Komatsu Y; Okuyama H; Baba E; Sakai D; Watanabe T; Tamura T; Yamashita K; Gosho M; Shimada Y
    Oncologist; 2018 Jan; 23(1):7-15. PubMed ID: 28894015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial.
    Pfeiffer P; Yilmaz M; Möller S; Zitnjak D; Krogh M; Petersen LN; Poulsen LØ; Winther SB; Thomsen KG; Qvortrup C
    Lancet Oncol; 2020 Mar; 21(3):412-420. PubMed ID: 31999946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.
    Eng C; Kim TW; Bendell J; Argilés G; Tebbutt NC; Di Bartolomeo M; Falcone A; Fakih M; Kozloff M; Segal NH; Sobrero A; Yan Y; Chang I; Uyei A; Roberts L; Ciardiello F;
    Lancet Oncol; 2019 Jun; 20(6):849-861. PubMed ID: 31003911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
    Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
    Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.